Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Sellas Life Sciences Group
University of Illinois at Chicago
Kura Oncology, Inc.
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)
Faron Pharmaceuticals Ltd
Dana-Farber Cancer Institute
Prelude Therapeutics
Massachusetts General Hospital
CellCentric Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AbbVie
OHSU Knight Cancer Institute
Prelude Therapeutics
First Affiliated Hospital of Zhejiang University
AbbVie